"2/ Novogen have stated that they do not have the funds to do both oncology and non oncology, so they will stick with their main target, they have already said that."
have enough money to pay wages to ex CEO and two extra directors however
Lilly's CEO keeps faith in the pipeline as biotech gets 'too expensive', page-7
Add to My Watchlist
What is My Watchlist?